Author: Lucy Chard 27th March 2026

Cell and gene therapy (CGT) is revolutionizing healthcare, offering transformative solutions for diseases that were once considered untreatable. In the United States, the CGT market is rapidly advancing, driven by scientific innovation, regulatory developments, and strategic investments. This article explores the current state of play for cell and gene therapy in the US, focusing on market dynamics, regulatory pathways, manufacturing challenges, commercial strategies, and future growth prospects. 

Cell & Gene Therapy: Current State of Play in the US Market Landscape 

The United States is a global leader in cell and gene therapy innovation, with a robust pipeline of therapies targeting rare genetic disorders, cancers, and chronic diseases. As of 2026, the US CGT market is valued at billions of dollars, with projections indicating exponential growth over the next decade. This growth is fueled by advancements in biotechnology, increased investment from pharmaceutical companies, and a growing number of FDA-approved therapies. 

Key players in the US CGT market include Novartis, Bristol Myers Squibb, and Bluebird Bio, among others. These companies are pioneering therapies such as CAR-T cell treatments for cancer and gene therapies for inherited conditions like spinal muscular atrophy. Collaborations between biotech firms, academic institutions, and contract development and manufacturing organizations (CDMOs) are essential for accelerating innovation and commercialization. 

Globally, the cell and gene therapy manufacturing market is experiencing unprecedented growth. Nova1Advisor in their Cell & Gene Therapy Analysis Report [1] quoted: 

“The global cell and gene therapy manufacturing market size was estimated at US$21.15 billion in 2025 and is projected to hit around US$215.18 billion by 2035, growing at a CAGR of 26.11% during the forecast period from 2026 to 2035.”  

This remarkable predicted growth underscores the increasing demand for CGTs and the critical role of manufacturing in scaling these therapies for widespread use. 

Regulatory Pathway Developments and Approval Trends 

The regulatory landscape for cell and gene therapies in the United States has evolved significantly in recent years. The FDA has introduced specialized frameworks to expedite the approval of CGTs, including the Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy designation. These pathways aim to streamline clinical trials and accelerate the market entry for promising therapies. 

Approval trends reflect growing acceptance of CGTs, with the FDA approving several landmark therapies in recent years [2]. For instance, Zolgensma, a gene therapy for spinal muscular atrophy, and Kymriah, a CAR-T cell therapy for leukemia, have set new benchmarks for efficacy and safety. However, the regulatory process remains complex, requiring rigorous evidence of clinical benefit, long-term safety, and manufacturing consistency. 

Despite these advancements, challenges persist. Regulatory agencies must balance innovation with patient safety, particularly for therapies with limited long-term data. Additionally, the high cost of CGTs raises questions about affordability and equitable access, which are critical for realizing their full societal value. 

Manufacturing Challenges and Scalability Considerations 

Manufacturing is one of the most significant hurdles in the cell and gene therapy sector. Unlike traditional pharmaceuticals, CGTs involve complex processes such as cell isolation, genetic modification, and cryopreservation. These processes must be conducted under stringent conditions to ensure product quality and safety. 

Scalability is a major concern for CGT manufacturing. As demand for these therapies grows, companies must invest in advanced manufacturing technologies and infrastructure to meet production needs. Automation, closed-system manufacturing, and artificial intelligence are emerging as key solutions to enhance scalability and reduce costs. 

The Office of Health Economics stated in their Contract Research Report - The Value of Cell and Gene Therapies to the UK Economy [3]: 

“Wider access to cell and gene therapies could be supported by a shift in technology, infrastructure, behavior, and policy, which in turn could realize diverse health-related benefits. Such a system shift is likely to require investment beyond the reimbursement of individual health technologies.” 

Another challenge is the supply chain. CGTs often require personalized manufacturing, which complicates logistics and increases costs. Companies are exploring innovative approaches, such as decentralized manufacturing and partnerships with CDMOs, to address these issues.  

Commercial Strategies for Advanced Therapy Products 

Commercializing cell and gene therapies requires a multifaceted approach that addresses existing issues with pricing, reimbursement, and patient access. Given the high cost of CGTs, pharmaceutical companies are adopting innovative pricing models, such as outcomes-based agreements, where payment is tied to the therapy's clinical success. 

Patient access is another critical area where change is needed. Companies are working to expand access to CGTs through partnerships with healthcare providers, payers, and advocacy groups. Education campaigns aimed at healthcare professionals and patients are also essential for increasing awareness and adoption of these therapies. 

The value of CGTs extends beyond purely clinical outcomes. These therapies have the potential to improve productivity, reduce absenteeism, and enhance the quality of life for patients and caregivers. As noted by the Office of Health Economics: 

 “Our findings demonstrate the substantial societal value of CGTs, derived from increased productivity, reduced absenteeism, and enhanced quality of life for patients and caregivers.” 

Future Outlook for Cell and Gene Therapy Market Growth 

The future of cell and gene therapy in the United States is promising, with several trends shaping the market's trajectory. Advances in gene-editing technologies, such as CRISPR, are enabling the development of more precise and effective therapies [4]. Additionally, the integration of artificial intelligence and big data analytics is accelerating drug discovery and optimizing clinical trials. 

The market is also expected to benefit from increased investment in CGT infrastructure, Nova1Advisor claim the CRISPR-based Gene Editing Market will grow [5] from a value of USD 7.25 billion in 2025 to reach around USD 28.77 billion by 2035, growing at a CAGR of 14.78% across the decade. 

The US government and private sector are allocating significant resources to support research, manufacturing, and commercialization. These investments are critical for addressing challenges related to scalability and affordability. 

Emerging therapeutic areas, such as regenerative medicine and immunotherapy, are expanding the scope of CGTs. These innovations have the potential to address unmet medical needs and improve patient outcomes across a wide range of diseases. 

Conclusion 

Cell and gene therapy represents a paradigm shift in healthcare, offering transformative solutions for patients with previously untreatable conditions. The United States is leading the way in CGT innovation, with a dynamic market landscape, supportive regulatory frameworks, and ongoing efforts to overcome manufacturing and scalability challenges. 

As the field continues to evolve, widening access to CGTs will require a concerted effort from stakeholders across the healthcare ecosystem. Investments in technology, infrastructure, and policy will be essential for realizing the full potential of these therapies and delivering their substantial societal value.